144872-10-6

Upstream product

• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 609-08-5 Diethyl methylmalonate 
• 141352-95-6 Diethyl methyl-p-nitrobenzyl-malonate 
• 54777-65-0 4-acetamidobenzyl chloride 
• 144872-09-3 diethyl methyl-(4-acetamido)benzylmalonate 

Downstream Products

• 144871-84-1 diethyl methyl-(4-benzylamino)benzylmalonate 
• 144871-86-3 2-methyl-3-(4-benzylamino)phenyl propionic acid 
• 144871-85-2 Methyl-(4-benzylamino)benzylmalonic acid 
• 1333468-75-9 2-(4-(4-methylpiperazin-1-yl)benzyl)propanamide 
• 1333468-74-8 2-(4-(4-methylpiperazin-1-yl)benzyl)propanoic acid 
• 1333468-73-7 diethyl 2-(4-(4-methylpiperazin-1-yl)benzyl)-2-methylmalonate 
• 1333468-72-6 diethyl 2-(4-(piperazin-1-yl)benzyl)-2-methylmalonate 

Relevant academic research and scientific papers

Inhibitors of protein kinases

Compounds of general Formula (I): wherein R1, R2, R3, Ra, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.

8-substituted purines as selective adenosine receptor agents

The present invention relates to certain novel 8-substituted purines as selective A 1 -adenosine receptor antagonists which are useful in the treatment of patients suffering from Alzheimer''s disease, congestive heart failure or pulmonary bronchoconstrict